Pharmacogenomics (PGx) Market Size – USD 5.66 Billion in 2018, Market Growth - CAGR of 8.7%, Pharmacogenomics (PGx) Industry Trends – Reduced multiple doses of the drug per day

New York, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Growing demand for personalized therapy, increasing prevalence of target chronic diseases, technological advancements, favorable government initiatives, availability of financial support for research and development are key factors contributing to high CAGR of Pharmacogenomics Market during forecast period.

According to the current analysis of Reports and Data, the global Pharmacogenomics (PGx) market was valued at USD 5.66 billion in 2018 and is expected to reach USD 11.01 billion by the year 2026, at a CAGR of 8.7%. Pharmacogenomics is the study of the drug interaction with an individual’s genes. This technology shows how inherited genes affect the way medications work for each person. Various drugs act in different manner for each individual, as each of the individual inherit different gene thus one drug can be effective and safe for a person but it may be harmful for another people. Rising incidences of bizarre adverse drug reactions and resistance to the therapeutic treatments such as increasing cases of antibiotic resistance cases, and non-registered adverse reactions to drugs from sulpha-class and others are giving rise to the demand for personalized medicine which leading the growth of the pharmacogenomics market.

Request free sample of this research report at: https://www.reportsanddata.com/sample-enquiry-form/2296

Personalized medicine is the alteration of medical treatment as per the individual characteristics of each patient. These medicines use an individual’s genetic information to provide efficient and effective pharmacological activity. In cancer, personalized medicine uses specific information of tumor to diagnose, plan the treatment, find out how well treatment is working, or make a prognosis. For example, personalized medicine is used in case of HER-2 positive breast cancer to detect the tumor cells and treat the cancer. Oncology is among the first medical specialties to apply personalized medicine other than cancer it is applicable in various target cell diseases such as various infections, cardiovascular diseases and others.

Severe technological developments are the major factor fueling the demand of pharmacogenomics in the market field. For instance, the SmatAmp method enables the detection of genetic polymorphisms or mutations in target genes within 30-40 min without DNA isolation and PCR amplification. Increasing Foreign Direct investment (FDI), globalization and medical tourism are enhancing the surge for drug discovery and development in pharmaceutical & biopharmaceutical companies, leading to increased demand of the pharmacogenomics market. However, high cost in association with processing and high capital investment for R&D of pharmacogenomics (PGx) study, and lack of skilled personnel may hamper the market growth.     

Further key findings from the report suggest

• Various players in pharmacogenomics market are engaged in promoting user friendly techniques. For instance, Abbott has launched a new point-of-care test called m-PIMA HIV-1/2 VL in the Netherlands for quick, accurate and easy management of human immunodeficiency virus (HIV) infection
• During 2019-2026, pharmacogenomics (PGx) market is expected to register a CAGR of 9.7% in Asia Pacific; followed by North America and Europe, with 8.8% and 8.4% CAGR, respectively. High prevalence of chronic target diseases across the globe is the major factor driving the market during the forecast period across all regions.
• The PCR technology among other pharmacogenomics technologies dominates the market with highest market share in the year 2018. It is estimated to grow at a CAGR of 9.1% during the forecast period to reach USD 3.56 billion by 2026
• Based on application segment, the oncology is expected to account for the CAGR 8.8% of the global pharmacogenomics market, as increasing prevalence of cancer across the world
• Asia Pacific is expected to account for the CAGR 9.7% of the global pharmacogenomics market. Developing nations such China, and India are likely to witness high growth due to high prevalence of target diseases, increased healthcare expenditure and high CROs and FDI to promote R&D practices in the region
• Slow rate of commercialization, high costs involved in research and development, and lack of skilled professionals are among the key factors likely to hamper growth of the market
• Key participants include Abbott Laboratories, Admera Health, LLC, Agena Biosciences, Inc., Cancer Genetics, Inc., Dynamic DNA Laboratories, F. Hoffmann-La Roche Ltd, geneOmbio Technologies Pvt Ltd., Genomic Health, Inc., Illumina, Inc., Laboratory Corporation of America Holdings

To identify the key trends in the industry, click on the link below:   https://www.reportsanddata.com/report-detail/pharmacogenomics-pgx-market

Segments covered in the report:

For the purpose of this report, Reports and Data has segmented the pharmacogenomics (PGx) market on the basis of products & services, technology, application, end use, and region:                     

Products & Services Outlook (Revenue, USD Million; 2016-2026)

• Products
  • Kits
  • Assay & Reagents
  • Instruments
  • Software
• Services
  • Genotyping
  • SNP Identification
  • Pharmacogenetic Testing
  • Other Services

Technology Outlook (Revenue, USD Million; 2016-2026)

• Polymerase Chain Reaction (PCR)
  • Real Time PCR
  • qPCR
  • Digital PCR
• DNA Sequencing/Next Generation Sequencing (NGS)
• Nucleic Acid Amplification Tests (NAATs)
• Mass Spectrometry
• Gel Electrophoresis
• Hybridization
  • Fluorescence In Situ Hybridization (FISH)
  • Chromogenic In Situ Hybridization (CISH)
  • Others
• Microarray
• Others

Application Outlook (Revenue, USD Million; 2016-2026)

• Oncology
• Infectious Diseases
• Neurology/Psychiatry
• Cardiovascular
• Others

End Use Outlook (Revenue, USD Million; 2016-2026)

• Research Organisation
• Pharmaceutical Companies
• Diagnostic Centers
• Others

Order Now: https://www.reportsanddata.com/checkout-form/2296

Regional Outlook (Revenue in USD Billion; 2016–2026)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of the Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Rest of Asia-Pacific
• Middle East & Africa
  • Latin America
• Brazil

Browse more similar reports on Biotechnology category by Reports And Data

In vivo CRO Market - https://www.reportsanddata.com/report-detail/in-vivo-cro-market

Cell Surface Markers Market - https://www.reportsanddata.com/report-detail/cell-surface-markers-market

Gene Expression Market - https://www.reportsanddata.com/report-detail/gene-expression-market

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:
John Watson
Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-800-819-3052
E-mail: sales@reportsanddata.com